Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Phio Pharmaceuticals Corp. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 11 | 11 | 0 |
| Shares | 100.6K | 164.7K | +64.1K (+63.7%) |
| Value | $130.8K | $387.4K | +$256.5K (+196.1%) |
New holders (4)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 48,665 | $114.4K | 0.00% |
| Virtu Financial LLC | 14,298 | $34.0K | 0.00% |
| Royal Bank of Canada | 3,464 | $8.00K | 0.00% |
| Mount Yale Investment Advisors, LLC | 27 | $63 | 0.00% |
Sold out (4)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| XTX Topco Ltd | 10,800 | $14.0K |
| Tower Research Capital LLC (TRC) | 2,501 | $3.25K |
| UBS Group AG | 103 | $134 |
| Barclays PLC | 5 | $7 |